New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore
This article was originally published in SRA
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.
You may also be interested in...
Singapore's efforts to consolidate and streamline the regulatory control of all health products under a single legislation has resulted in the fine-tuning of certain regulatory provisions that drug companies should be aware of.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.